
    
      This is a pilot clinical study of CCM in addition to optimal medical therapy (OMT) over a 24
      week period.The primary endpoint shall be mean change from baseline to 24 weeks in Kansas
      City Cardiomyopathy Questionnaire (KCCQ) overall score (reflecting integrated information on
      physical limitations, symptoms, self-efficacy, social interference and quality of life).

      This pilot study will collect efficacy and safety data in heart failure patients having NYHA
      class II and III symptoms despite appropriate medication with baseline ejection fraction
      equal or greater than 50% (HFpEF populations).
    
  